ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026Pooled it
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.Molecular imaging · 2022Pooled it
- Imaging Patients with Metastatic Castration-Resistant Prostate Cancer UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Trial
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy.Nuclear medicine and molecular imaging · 2026Review
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.Biomedicines · 2026Review
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers.European journal of nuclear medicine and molecular imaging · 2025Article
- From Desferrioxamine B Umpolung to an Enantiopure Bifunctional Chelator forChemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- The Role of STEAP1 in Prostate Cancer: Implications for Diagnosis and Therapeutic Strategies.Biomedicines · 2025Review
- Single Chelator-Minibody Theranostic Agents forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2024Article
- PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?Theranostics · 2024Article
- Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024Review
- From Bench to Bedside: Patient-Oriented Radiopharmaceutical Development in Nuclear Medicine Based on the Example of [Molecules (Basel, Switzerland) · 2023Review
- Phenomic Imaging.Phenomics (Cham, Switzerland) · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
We conducted a phase I dose-escalation study with
methodsPatients received 185 MBq (5 mCi) of
resultsEighteen patients were injected and scanned without side effects. Whole-body clearance was monoexponential, with a median biologic half-life of 215 h, whereas serum clearance showed biexponential kinetics, with a median biologic half-life of 3.7 (12.3%/L) and 33.8 h (17.9%/L). The radiation absorbed dose estimates were 1.67, 1.36, and 0.32 mGy/MBq to liver, kidney, and marrow, respectively, with an effective dose of 0.41 mSv/MBq (1.5 rem/mCi). Both skeletal and nodal lesions were detected with
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.